Achieve Clinical Research, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$260,406	6
2024	Research	$32,290	2
2021	Research	$654	1
2020	Research	$7,120	2
2019	Research	$56,492	13

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $276,906 7 payments
Merck Sharp & Dohme Corporation $55,166 14 payments
Sanofi Pasteur Inc. $15,790 1 payment
Biogen, Inc. $7,100 1 payment
Teva Pharmaceuticals USA, Inc. $2,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $114,249 1 payment
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $103,522 3 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU $37,013 2 payments
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older $23,334 1 payment
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $19,207 1 payment
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $17,308 1 payment
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $16,595 1 payment
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). $15,790 1 payment
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia $7,100 1 payment
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine $2,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.